NovaBridge Biosciences
NBP
$1.70
-$0.08-4.49%
NASDAQ
| 06/30/2026 | 12/31/2025 | 09/30/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 245.76% | 134.87% | -26.76% | -26.76% | -68.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 186.37% | 445.21% | -27.58% | -27.58% | -58.49% |
| Operating Income | -186.37% | -445.21% | 27.58% | 27.58% | 58.49% |
| Income Before Tax | -244.00% | -571.87% | 66.68% | 66.68% | 38.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -244.00% | -571.87% | 66.68% | 66.68% | 38.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -244.00% | -571.87% | 66.68% | 66.68% | -121.65% |
| EBIT | -186.37% | -445.21% | 27.58% | 27.58% | 58.49% |
| EBITDA | -186.57% | -446.00% | 27.60% | 27.60% | 58.33% |
| EPS Basic | -142.77% | -374.08% | 73.94% | 73.94% | -121.46% |
| Normalized Basic EPS | -144.89% | -362.38% | 22.24% | 22.24% | 38.99% |
| EPS Diluted | -142.77% | -374.08% | 73.94% | 73.94% | -121.46% |
| Normalized Diluted EPS | -144.89% | -362.38% | 22.24% | 22.24% | 38.99% |
| Average Basic Shares Outstanding | 41.64% | 41.77% | 27.87% | 27.87% | 0.95% |
| Average Diluted Shares Outstanding | 41.64% | 41.77% | 27.87% | 27.87% | 0.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |